Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
Oral disorder07.05.01.0050.000846%Not Available
Gastrointestinal sounds abnormal07.01.01.002--Not Available
Skin mass23.07.04.014--Not Available
Brain injury19.07.03.007; 17.11.01.0030.000470%Not Available
Cholestatic liver injury09.01.07.0160.000470%Not Available
Hypertransaminasaemia09.01.02.0050.000313%Not Available
Anorectal discomfort07.03.03.0030.000313%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.002976%
X-linked lymphoproliferative syndrome03.17.01.002; 01.13.02.003; 16.21.02.003; 11.05.10.005; 10.03.01.003--Not Available
Epstein-Barr virus associated lymphoproliferative disorder01.13.02.002; 16.21.02.002; 11.05.10.0010.000940%Not Available
Acute kidney injury20.01.03.0160.003916%
Upper-airway cough syndrome22.12.03.0360.000627%
Foetal growth restriction18.03.01.0020.000470%
Gestational hypertension24.08.07.004; 18.02.03.0040.000470%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.001723%
Macular fibrosis06.09.03.0140.000470%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.002350%Not Available
Granulomatosis with polyangiitis24.12.04.011; 22.01.01.015; 20.05.01.013; 10.02.02.0180.000470%Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.000627%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.006423%Not Available
Diffuse alopecia23.02.02.0070.000627%Not Available
Autoimmune haemolytic anaemia10.04.01.005; 01.06.01.0040.000627%Not Available
Faeces soft07.01.03.0080.000313%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.007--Not Available
Noninfective sialoadenitis07.06.04.0030.000313%Not Available
Stenosis08.01.03.0600.000627%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.003446%
Anal incontinence17.05.01.021; 07.01.06.0290.000627%
Abdominal mass07.01.01.003--Not Available
The 21th Page    First    Pre   21 22 23 24 25    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene